Home » Stocks » ALKS

Alkermes PLC (ALKS)

Stock Price: $22.00 USD -0.01 (-0.05%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 3.57B
Revenue (ttm) 1.04B
Net Income (ttm) -94.63M
Shares Out 160.45M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE 39.37
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $22.00
Previous Close $22.01
Change ($) -0.01
Change (%) -0.05%
Day's Open 22.07
Day's Range 21.94 - 22.49
Day's Volume 3,003,267
52-Week Range 14.52 - 23.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

An agreement with an activist investor capped a busy month.

17 hours ago - The Motley Fool

Keeping track of upcoming events is important.

Other stocks mentioned: HRTX
1 day ago - The Motley Fool

DUBLIN, May 5, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesday...

2 days ago - PRNewsWire

DUBLIN, May 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during ...

5 days ago - PRNewsWire

DUBLIN, April 30, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has reached an agreement with Sarissa Capital Management LP ("Sarissa Capital"), a beneficial owner of approxim...

1 week ago - PRNewsWire

Alkermes' (ALKS) earnings rise year over year in the first quarter of 2021. Revenues surpass estimates.

1 week ago - Zacks Investment Research

Alkermes (ALKS) delivered earnings and revenue surprises of 320.00% and 10.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Alkermes (NASDAQ:ALKS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 1000.00% year over year to $0.11, which beat the estimate of ($0.02).

1 week ago - Benzinga

DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational enginee...

1 week ago - PRNewsWire

DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2021. "Our first quarter results reflect solid execution against our strategy...

1 week ago - PRNewsWire

DUBLIN, April 27, 2021 /PRNewswire/ -- Myrelationshipwithalcohol.com, a new website sponsored by Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), goes live today to offer education about alc...

1 week ago - PRNewsWire

Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 ...

1 week ago - Benzinga

DUBLIN, April 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nem...

1 week ago - PRNewsWire

DUBLIN, April 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

2 weeks ago - PRNewsWire

DUBLIN, April 20, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International ...

2 weeks ago - PRNewsWire

Alkermes (ALKS) signs a clinical trial collaboration and supply agreement with Merck to evaluate nemvaleukin alfa in combination with Keytruda for treating platinum-resistant ovarian cancer.

Other stocks mentioned: MRK
4 weeks ago - Zacks Investment Research

DUBLIN, April 7, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical trial collaboration and supply agreement with MSD (a tradename of Merck & Co., Inc. ...

1 month ago - PRNewsWire

DUBLIN, March 25, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at Stifel's 3rd Annual CNS Day on Thursday, Apr. 1, 2021 a...

1 month ago - PRNewsWire

DUBLIN, March 25, 2021 /PRNewswire/ -- Today, Alkermes plc (Nasdaq: ALKS) will host a virtual Investor Day to discuss the company's research and development strategy and portfolio, including updates fro...

1 month ago - PRNewsWire

DUBLIN, March 11, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered inte...

1 month ago - PRNewsWire

DUBLIN, Feb. 18, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday...

2 months ago - PRNewsWire

Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.

2 months ago - Zacks Investment Research

The biotech posted a big year-over-year sales decline. But there was a good reason for it.

2 months ago - The Motley Fool

Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the company's ...

3 months ago - PRNewsWire

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual J.P. Morg...

4 months ago - PRNewsWire

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, part...

Other stocks mentioned: BMRN, IONS
4 months ago - Forbes

DUBLIN, Dec. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug Application (NDA) re...

4 months ago - PRNewsWire

Alkermes (ALKS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

Alkermes' (ALKS) Value Enhancement Plan is set to drive growth, improve operational and financial performance, as well as enhance shareholder value.

4 months ago - Zacks Investment Research

The biotech has a plan to increase profitability.

4 months ago - The Motley Fool

DUBLIN, Dec. 10, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance and enhan...

4 months ago - PRNewsWire

Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.

5 months ago - Zacks Investment Research

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Dru...

5 months ago - PRNewsWire

Alkermes plc (ALKS) CEO Richard Pops on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.

6 months ago - Zacks Investment Research

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical difficulties...

6 months ago - PRNewsWire

Alkermes (ALKS) delivered earnings and revenue surprises of 2700.00% and 11.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2020 and provided updated financial expectations for full-year 2020. "Over the...

6 months ago - PRNewsWire

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss the company'...

6 months ago - PRNewsWire

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma companies th...

Other stocks mentioned: NBIX, ACAD, ARWR, BMRN, IONS
6 months ago - Forbes

Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.

6 months ago - Zacks Investment Research

An FDA joint committee's favorable votes on an Alkermes drug candidate to treat bipolar I and schizophrenia came just weeks ahead of an expected key FDA decision and sent ALKS stock rising. The post Alk...

6 months ago - Investors Business Daily

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety a...

6 months ago - PRNewsWire

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic...

6 months ago - PRNewsWire

DUBLIN, Oct. 7, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2020 joint ...

7 months ago - PRNewsWire

LGND vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: LGND
7 months ago - Zacks Investment Research

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleuk...

7 months ago - PRNewsWire

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych...

7 months ago - PRNewsWire

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizop... [Read more...]

Industry
Biotechnology
IPO Date
Jul 16, 1991
Stock Exchange
NASDAQ
Ticker Symbol
ALKS
Full Company Profile

Financial Performance

In 2020, Alkermes's revenue was $1.04 billion, a decrease of -11.29% compared to the previous year's $1.17 billion. Losses were -$110.86 million, -43.62% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Alkermes stock is "Hold." The 12-month stock price forecast is 22.11, which is an increase of 0.50% from the latest price.

Price Target
$22.11
(0.50% upside)
Analyst Consensus: Hold